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ABSTRACT
OBJECTIVE
To assess the efficacy and safety of dual sodium 
glucose cotransporter (SGLT) 1/2 inhibitor 
sotagliflozin in type 1 diabetes mellitus.
DESIGN
Meta-analysis of randomised controlled trials.
DATA SOURCES
Medline; Cochrane Library; Embase; international 
meeting abstracts; international and national clinical 
trial registries; and websites of US, European, and 
Japanese regulatory authorities, up to 10 January 2019.
ELIGIBILITY CRITERIA FOR SELECTING STUDIES
Randomised controlled trials evaluating the effect of 
sotagliflozin versus active comparators or placebo 
on glycaemic and non-glycaemic outcomes and on 
adverse events in type 1 diabetes in participants 
older than 18. Three reviewers extracted data for 
study characteristics, outcomes of interest, and 
risk of bias and summarised strength of evidence 
using the grading of recommendations assessment, 
development, and evaluation approach. Main 
outcomes were pooled using random effects models.
RESULTS
Of 739 records identified, six randomised placebo 
controlled trials (n=3238, duration 4-52 weeks) were 
included. Sotagliflozin reduced levels of glycated 
haemoglobin (HbA1c; weighted mean difference 
−0.34% (95% confidence interval −0.41% to 
−0.27%), P<0.001); fasting plasma glucose (−16.98 
mg/dL, −22.1 to −11.9; 1 mg/dL=0.0555 mmol/L) 
and two hour-postprandial plasma glucose (−39.2 
mg/dL, −50.4 to −28.1); and daily total, basal, and 
bolus insulin dose (−8.99%, −10.93% to −7.05%; 
−8.03%, −10.14% to −5.93%; −9.14%, −12.17% 
to −6.12%; respectively). Sotagliflozin improved 
time in range (weighted mean difference 9.73%, 
6.66% to 12.81%) and other continuous glucose 
monitoring parameters, and reduced body weight 
(−3.54%, −3.98% to −3.09%), systolic blood pressure 
(−3.85 mm Hg, −4.76 to −2.93), and albuminuria 
(albumin:creatinine ratio −14.57 mg/g, −26.87 
to −2.28). Sotagliflozin reduced hypoglycaemia 
(weighted mean difference −9.09 events per patient 
year, −13.82 to −4.36) and severe hypoglycaemia 
(relative risk 0.69, 0.49 to 0.98). However, the drug 
increased the risk of ketoacidosis (relative risk 3.93, 
1.94 to 7.96), genital tract infections (3.12, 2.14 to 
4.54), diarrhoea (1.50, 1.08 to 2.10), and volume 
depletion events (2.19, 1.10 to 4.36). Initial HbA1c 
and basal insulin dose adjustment were associated 
with the risk of diabetic ketoacidosis. A sotagliflozin 
dose of 400 mg/day was associated with a greater 
improvement in most glycaemic and non-glycaemic 
outcomes than the 200 mg/day dose, without 
increasing the risk of adverse events. The quality of 
evidence was high to moderate for most outcomes, 
but low for major adverse cardiovascular events and 
all cause death. The relatively short duration of trials 
prevented assessment of long term outcomes.
CONCLUSIONS
In type 1 diabetes, sotagliflozin improves glycaemic 
and non-glycaemic outcomes and reduces 
hypoglycaemia rate and severe hypoglycaemia. The 
risk of diabetic ketoacidosis could be minimised by 
appropriate patient selection and down-titration of 
the basal insulin dose.
Introduction
Type 1 diabetes mellitus affects 1.5 million people 
in the United States alone and its prevalence is 
continuously rising, partly because over 10% of 
patients initially presumed to have type 2 diabetes 
at diagnosis subsequently show evidence of islet 
autoimmunity and progress to insulin dependence 
later on.1 2 The achievement and maintenance of 
glycaemic goals in type 1 diabetes has proven both 
difficult and hazardous. In the T1D Exchange clinic 
registry, the average level of glycated haemoglobin 
(HbA1c) was 8%, only 30% of patients with type 1 
diabetes achieved an HbA1c goal of 7%, and severe 
WHAT IS ALREADY KNOWN ON THIS TOPIC
In patients with type 1 diabetes mellitus, 30% achieve glycaemic targets and are 
encumbered by unwanted effects of insulin, namely hypoglycaemia and weight 
gain; severe hypoglycaemia, in particular, is the main factor limiting optimal 
glucose control and a risk factor for adverse events in diabetes
Sotagliflozin is a novel, dual sodium glucose co-transport (SGLT) 1/2 inhibitor 
that inhibits intestinal glucose absorption as well as renal glucose reabsorption; 
this mechanism of action could blunt postprandial glycaemic excursions and 
glycaemic variability, eventually reducing the need for bolus insulin corrections 
and hypoglycaemic risk
Sotagliflozin has completed phase III clinical development in type 1 diabetes, 
but the evidence regarding its efficacy and safety in this population has not been 
systematically reviewed
WHAT THIS STUDY ADDS
Compared with placebo, sotagliflozin improves glycaemic and non-glycaemic 
outcomes (including markers of diabetic nephropathy) and reduces the incidence 
of hypoglycaemia and of severe hypoglycaemia
Diabetic ketoacidosis (DKA) is the main adverse event associated with 
sotagliflozin treatment, and its risk depends on initial HbA1c levels in patients 
and reduction of the basal insulin dose during treatment; sotagliflozin is also 
associated with an increased risk of genital tract infections and diarrhoea, but 
not of urinary tract infections
Current evidence on long term outcomes is limited by the short duration of 
individual trials
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hypoglycaemia occurred in up to 20% of patients 
per year.3 Similarly, in the Diabetes Complications 
and Control Trial, patients with type 1 diabetes with 
HbA1c levels within target showed a 2.9-fold increased 
cardiovascular mortality,4 and patients in the intensive 
intervention group escalated back to an HbA1c of 8% 
in the years following the trial.5
Insulin is the mainstay of treatment for type 
1 diabetes, but has unwanted effects, including 
hypoglycaemia and weight gain.6 Severe hypoglycaemia 
in particular is the main factor limiting optimal glucose 
control in the disease; it is frequent, adds costs to 
diabetes management, and is a strong predictor of 
adverse vascular and non-vascular outcomes and 
death.6-9 None of the adjunctive treatments approved 
(that is, pramlintide) or recently proposed for type 1 
diabetes (that is, metformin, incretin analogues, and 
sodium glucose cotransporter (SGLT) 2 inhibitors) has 
reduced the incidence of hypoglycaemia and severe 
hypoglycaemia, which remain the major unresolved 
issue in the management of these patients.10-20
SGLT1 is responsible for glucose absorption in the 
proximal intestine, and missense mutations in SGLT1 
gene have been associated with protection from 
glucose intolerance, obesity, and cardiometabolic 
risk in population based studies.21 Sotagliflozin 
(LX4211, SAR439954) is a novel, first-in-class, dual 
inhibitor of SGLT1 and SGLT2; while SGLT2 inhibition 
reduces glucose reabsorption in the renal tubule, 
SGLT1 inhibition decreases glucose absorption in the 
intestine. This dual mechanism of action could offer 
incremental benefits over selective SGLT2 inhibitors22 
by blunting postprandial glycaemic excursions and 
glycaemic variability, lowering the need for bolus 
insulin correction doses, and eventually reducing 
hypoglycaemic risk.23 Furthermore, reduced glucose 
absorption in the proximal intestine increases glucose 
delivery to the distal intestine, stimulating incretin 
glucagon-like peptide-1 (GLP-1).24 In preclinical models, 
the increased release of incretin has enhanced weight 
loss and counteracted glucagon induced ketogenesis,25 
which could reduce the risk of diabetic ketoacidosis.23-25
Sotagliflozin has recently reached phase III 
development in patients with type 1 diabetes26-31 but 
randomised controlled trials evaluating this drug 
have not been systematically reviewed. To clarify the 
evidence base of this novel approach, we conducted 
a meta-analysis of randomised controlled trials 
evaluating the efficacy and safety of sotagliflozin in 
adults with type 1 diabetes.
Methods
Data sources and searches
We searched English and non-English language 
publications up to 10 January 2019 on the following 
databases and international and national clinical trial 
registries: Ovid Medline, Ovid Medline Epub Ahead 
of Print, Ovid Medline In-Process, Embase, Cochrane 
Database of Systematic Reviews, Epistemonikos, 
ClinicalTrials.gov, Cochrane CENTRAL Register 
of Controlled Trials, World Health Organization 
International Clinical Trials Registry Platform, 
European Union Clinical Trials Register, International 
Standard Randomised Controlled Trial Number registry, 
Australian New Zealand Clinical Trials Registry, and 19 
national clinical trial registries (full list of clinical trial 
registries provided in supplementary text). No language 
restrictions were applied. We also searched the US 
Food and Drug Administration,32 European Medicines 
Agency,33 and Japanese Pharmaceutical and Medical 
Devices Agency34 websites and drug manufacturers’ 
websites35 36 for relevant documents, and the American 
Diabetes Association and European Association for 
the Study of Diabetes meeting abstracts, which were 
subjected to the same assessment as regular articles.
Additionally, we emailed authors of relevant papers 
to verify results and methodological quality of retrieved 
articles, and drug manufacturers to inquire about 
further published and unpublished trials. We manually 
scanned reference lists from trials, review articles, and 
reports to identify any other relevant data. Search terms 
were “sodium glucose co-transport 1/2 inhibitors,” 
“dual sodium-glucose transport inhibitors,” 
“SGLT1/2 inhibitors,” “SGLT1 inhibitors,” “SGLT2 
inhibitors,” “SGLT1/2 inhibitor,” “sotagliflozin,” 
“LX4211,” “LP802034,” “SAR439954,” “Zynquista,” 
“management,” “therapy,” “treatment,” “trial,” 
“diabetes,” and “type 1 diabetes” (examples of online 
strategy run are provided in supplementary text).
Study selection
Inclusion criteria included English and non-English 
(French, Spanish, Portuguese, German, Chinese, 
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Japanese, Korean) articles of randomised controlled 
trials. Trial participants were aged 18 and older of any 
sex or ethnic origin, and the trials compared sotagliflozin 
with placebo or active comparators as an adjunct 
treatment to insulin in type 1 diabetes. We excluded 
non-human studies, non-randomised trials, letters or 
case reports, and articles not reporting outcomes of 
interest or primary data (editorials, reviews).
Outcome measures
We grouped evaluated outcomes into three broad 
groups: glycaemic efficacy outcomes, non-glycaemic 
outcomes, and safety outcomes. Glycaemic efficacy 
outcomes were:
• Changes in glycated haemoglobin (HbA1c) from 
baseline (primary outcome)
• Changes in levels of fasting plasma glucose
• Changes in two hour postprandial glycaemia 
(2h-PPG), as measured during an oral glucose 
tolerance test or a standardised mixed meal 
tolerance test. Many studies have linked 
postprandial glucose excursions to the risk of 
cardiovascular disease and report that targeting 
postprandial glycaemia rather than fasting 
plasma glucose lowers cardiovascular risk37 38
• Changes in total, basal, and bolus insulin dose 
(expressed as % of the initial insulin dose)
• Effect of SGLT1/2 inhibitors on daily urinary 
glucose excretion
• Continuous glucose monitoring parameters. 
Continuous glucose monitoring provides 
additional information to HbA1c and has been 
recently recommended for all adults with type 
1 diabetes and approved by the US Food and 
Drug Administration Advisory Committee.39 
We therefore assessed the following metrics of 
continuous glucose monitoring (described in the 
supplementary text): time in range (%), average 
daily glucose, standard deviation around average 
daily glucose, and mean amplitude of glucose 
excursion.40
Non-glycaemic outcome measures evaluated were 
changes in body weight, systolic and diastolic blood 
pressure; renal outcomes, defined as changes in 
estimated glomerular filtration rate (eGFR) and in 
albuminuria (expressed as urinary albumin:creatinine 
ratio, ACR), or need for renal replacement therapy; 
and changes in plasma lipids (triglyceride, low density 
lipoprotein-cholesterol, and high density lipoprotein-
cholesterol).
Safety measures were severe hypoglycaemia 
and any hypoglycaemia, diabetic ketoacidosis 
(definitions provided in the supplementary text), 
urinary tract infections, genital tract infections, 
other infections, gastrointestinal symptoms, major 
adverse cardiovascular events (MACE; cardiovascular 
death, myocardial infarction, stroke, admission 
owing to heart failure or unstable angina, or coronary 
revascularisation), cancer (overall and type specific), 
amputation, bone fracture, volume depletion, 
renal events, acidosis related events, drug induced 
liver injury, venous thromboembolism, serious 
adverse events, adverse events leading to treatment 
discontinuation, and all cause mortality. Volume 
depletion, acidosis related events, renal events, and 
serious adverse events were defined according to the 
Medical Dictionary for Regulatory Activities preferred 
items version 14.041 (supplementary text). We also 
planned to investigate whether the risk of diabetic 
ketoacidosis varied across different modes of insulin 
delivery (that is, MDI or CSI). All measures of dispersion 
were converted to standard deviations.
Data extraction and risk of bias assessment
Two reviewers (GM, RG) extracted data independently 
and in duplicate by using a predesigned data collection 
form, based on the Cochrane handbook for systematic 
reviews of intervention; discrepancies were arbitrated 
by a third reviewer and resolved by consensus. The 
agreement between the two reviewers for selection 
and validity assessment of trials was scored by the κ 
coefficient.
The quality of randomised controlled trials was 
assessed by the Cochrane Collaboration risk of bias 
tool.42 We also assessed sponsorship bias, which we 
included in the risk of bias tool. The 2018 Agency for 
Healthcare Research and Quality recommendations 
caution against equating industry sponsorship with 
high risk of bias and automatically downgrading 
the evidence for industry sponsorship.43 Therefore, 
for all included trials, we systematically assessed 
a prespecified list of eight items in trial designing, 
conducting, and reporting, which have been 
empirically linked to the risk of biased outcomes in 
industry funded trials and are not captured by the six 
domains of the risk of bias tool44-50 (supplementary 
table 1).
Data synthesis, analysis, and grading of evidence
The analysis was carried out in accordance with 
the Cochrane handbook of systematic reviews of 
interventions42 using Stata release 11.2 (StataCorp, 
College Station, TX, USA) and RevMan version 5.3.5 
(Nordic Cochrane Center, Copenhagen, Denmark),51 and 
was reported according to PRISMA guidelines52 (preferred 
reporting items for systematic reviews and meta-
analyses; see supplementary appendix). Treatments 
were evaluated on an intention-to-treat principle.
We calculated weighted mean differences and 
95% confidence intervals for continuous outcomes 
using an inverse variance random effects model. For 
dichotomous outcomes, we calculated risk ratios and 
95% confidence intervals by using the random effects 
Mantel-Haenszel approach with significance set at 
P=0.05. We conservatively used a priori a random 
effects model assuming a substantial variability 
in treatment effect size across studies. Statistical 
heterogeneity was assessed using the I2 statistic: 
with I2 values of 50% or over, we planned to explore 
individual study characteristics, and characteristics of 
subgroups of the main body of evidence.53
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We planned to conduct sensitivity analyses by 
repeating the analysis with alternative effect measures 
(odds ratio v relative risk), pooling methods (Peto 
v Mantel-Hanszel54), and statistical models (fixed v 
random effects) by excluding randomised controlled 
trials where we imputed values and randomised 
controlled trials at high risk of bias in any domains 
of the risk of bias tool. We also planned a priori 
subgroup analyses to explore potential effects on 
outcome measures of the following conditions: 
treatment duration (≤12 v >12 weeks), initial HbA1c 
levels (≥8% v <8%), duration of diabetes (<20 v ≥20 
years), background treatment (pretreatment insulin 
optimisation v stable insulin treatment), and presence 
and severity of renal dysfunction.
When trials evaluated different sotagliflozin doses, 
we planned to present data separately for each dose and 
to split sample size of the placebo group evenly among 
different dose comparisons.42 We explored interactions 
between different sotagliflozin doses and all outcomes 
primarily by comparing different dose groups within 
head-to-head trials (within-trial approach); we planned 
to verify robustness of this approach by also using 
across-trial comparison and meta-regression. Although 
the across-trial approach has a higher risk of ecological 
bias, it has a higher power than the within-trial 
approach, thus allowing us to rule out dose-response 
interactions with higher confidence.55
When eight or more comparisons were available, the 
effect of different SGLT1/2 inhibitor doses, baseline 
HbA1c, treatment duration, and diabetes duration 
on each outcome were assessed by meta-regression 
analysis (random effects model, within-study variance 
estimated with the unrestricted maximum likelihood 
method). Furthermore, the dose variable in the 
regression equation was treated categorically, with 
the starting dose coded as the baseline amount and 
each doubling of a drug dose considered to be a single 
increment increase. Publication bias was examined by 
funnel plots and the Egger test.
We used the grading of recommendations assessment, 
development, and evaluation (GRADE) approach to 
summarise the strength of evidence at outcome level 
and determine confidence in summary estimates for 
clinically relevant comparisons and outcomes.56 57 Three 
reviewers graded inconsistency, risk of bias, indirectness, 
imprecision, and publication bias for evidence related 
to the following areas: glycaemic efficacy (outcomes: 
HbA1c, fasting plasma glucose, 2h-PPG, time in 
range), non-glycaemic efficacy (outcomes: body 
weight, systemic blood pressure, eGFR, albuminuria), 
and adverse events (outcomes: hypoglycaemia, severe 
hypoglycaemia, diabetic ketoacidosis, urinary and 
genital tract infections, diarrhoea, MACE, serious adverse 
events, adverse events leading to discontinuation, and 
mortality). We planned to manage missing data by 
contacting via email the corresponding authors. Where 
this method was unsuccessful, we planned to follow the 
approach described in Cochrane handbook of systematic 
reviews of intervention (chapter 7.6-7.8 and 16.1.342; 
see supplementary text).
Patient and public involvement
No patients were involved in the definition of the 
research question or the outcome measures, and 
interpretation or writing up of results. Data relating to 
the impact of the intervention on participants’ quality 
of life were not extracted. Where possible, results of 
this meta-analysis will be disseminated to the patient 
community or individual patients and families through 
the investigators of this meta-analysis.
Results
The flow of study selection is reported in figure 
1. At the end of selection, six placebo controlled 
randomised trials (duration 4-52 weeks) enrolling 
3238 participants with type 1 diabetes were included 
in the meta-analysis26-31 58 59 (main characteristics 
reported in supplementary table 1). We excluded 
12 phase I trials conducted in individuals without 
diabetes, 18 trials enrolling patients with type 2 
diabetes (four completed, 14 active), and one trial 
enrolling patients without diabetes but with congestive 
heart failure (main characteristics of excluded trials 
reported in supplementary table 2). All included 
randomised controlled trials compared sotagliflozin 
with placebo on background insulin treatment. Three 
trials28 30 31 compared different sotagliflozin doses 
(75, 200, or 400 mg/day) with placebo. Overall, 10 
comparisons were available for the meta-analysis. 
Two trials adopted insulin dose optimisation (target: 
fasting plasma glucose 80-130 mg/dL and 2h-PPG 
>180 mg/dL; 1 mg/dL=0.0555 mmol/L) during the 
six weeks preceding randomisation.30 31 Two trials 
excluded patients with impaired renal function (eGFR 
<60 mL/min/1.73 m2),26 28 and four trials excluded 
patients with moderate-to-severe renal impairment 
(eGFR <45 mL/min/1.73 m2).27 29 30 31
Participants’ baseline characteristics were equally 
balanced between the study arms; in all randomised 
controlled trials, dropout rates were generally low 
and balanced across arms. No trial used the last-
observation-carried-forward approach to impute 
missing observations, which were imputed as non-
response for dichotomous outcomes. For continuous 
outcomes, we used mixed effects model-for-repeated-
measures statistics, based on the restricted maximum 
likelihood method for estimation. Two trials were 
partly funded by non-profit organisations,26 27 while 
a pharmaceutical company entirely funded four 
trials. However, we did not find any evidence of high 
risk of biased outcomes in trial design, conduct, 
and reporting. The overall quality was good for all 
included trials. The risk of bias summary for individual 
trials and the risk of bias graph for each item across 
included trials are detailed in supplementary table 1 
and summarised in supplementary figures 1-2. The 
analysis of funnel plots and the Egger test (P>0.67 for 
all outcomes) did not find any evidence of publication 
bias (supplementary figure 3). No values had to be 
imputed for the meta-analysis during data extraction. 
The agreement between the two reviewers was 0.96 
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for study selection and 0.89 for quality assessment of 
trials.
Glycaemic efficacy outcomes
HbA1c
Compared with placebo, sotagliflozin treatment was 
associated with a significant reduction in HbA1c levels 
(weighted mean difference −0.34%, 95% confidence 
interval −0.41% to −0.27%, P<0.001, I2=20%, 10 
comparisons, 3238 participants; fig 2). We saw little 
heterogeneity in the meta-analysis, suggesting a 
consistent drug effect. Subgroup and meta-regression 
analysis showed that the effect was independent of 
trial duration (β=0.110, P=0.28) and baseline HbA1c 
(β=0.119, P=0.38; supplementary table 3). HbA1c 
reduction with sotagliflozin at 400 mg/day was higher 
than with 200 mg/day (supplementary table 4).
Fasting plasma glucose and two hour-postprandial 
plasma glucose
Sotagliflozin significantly reduced fasting plasma 
glucose (weighted mean difference −16.98 mg/dL, 
95% confidence interval −22.09 to −11.86, P<0.001, 
I2=6%, 10 comparisons, 3238 participants) and 
2h-PPG (−39.24 mg/dL, −50.42 to −28.06, P<0.001, 
I2=20%, nine comparisons, 539 participants; fig 
2). We saw little heterogeneity in the meta-analysis, 
suggesting a consistent drug effect. The effect was 
independent of trial duration and baseline HbA1c 
(supplementary table 3).
Continuous glucose monitoring parameters
Four randomised controlled trials evaluated continuous 
glucose monitoring parameters.26 27 30 31 Compared 
with placebo, sotagliflozin significantly increased 
time in range (weighted mean difference 9.73%, 95% 
confidence interval 6.66% to 12.81%, P<0.001, I2=24%, 
six comparisons, 398 participants) and reduced 
average daily glucose (−15.09 mg/dL, −21.40 to −8.79, 
P<0.001, I2=28%, five comparisons, 312 participants), 
standard deviation around average daily glucose 
(−6.68 mg/dL, −10.59 to −2.77, P<0.001, I2=0%, five 
comparisons, 311 participants), and mean amplitude 
of glucose excursion (−19.52 mg/dL, −28.91 to −10.54, 
P<0.001, I2=0%, five comparisons, 311 participants; 
supplementary figure 4). We saw little heterogeneity in 
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Fig 1 | Flow diagram of evidence acquisition during study
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Test for overall effect: Z=1.94, P=0.05
Sotagliflozin 400 mg/day
  Baker 2017 (inTandem4)
  Bode 2017
  Buse 2018 (inTandem1)
  Danne 2018 (inTandem2)
  Garg 2017 (inTandem3)
  Sands 2015
Subtotal
Test for heterogeneity: τ2=0.00; χ2=2.95, df=5, P=0.71; I2=0%
Test for overall effect: Z=7.13, P<0.001
Total (95% CI)
Test for heterogeneity: τ2=4.54; χ2=9.62, df=9, P=0.38; I2=6%
Test for overall effect: Z=6.50, P<0.001
Test for subgroup differences: χ²=6.19; df=2, P=0.05; I²=67.7%
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Test for overall effect: Z=3.08, P=0.002
Sotagliflozin 400 mg/day
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Test for heterogeneity: τ2=0.00; χ2=3.25, df=4, P=0.52; I2=0%
Test for overall effect: Z=7.41, P<0.001
Total (95% CI)
Test for heterogeneity: τ2=57.31; χ2=9.97, df=8, P=0.27; I2=20%
Test for overall effect: Z=6.88, P<0.001
Test for subgroup differences: χ²=5.35; df=2, P=0.07; I²=62.6%
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Fig 2 | Forest plot comparing effect of sotagliflozin versus placebo on HbA1c (%), fasting plasma glucose (FPG), and 
two hour-postprandial plasma glucose (2h-PPG).1 mg/dL=0.0555 mmol/L. IV=inverse variance
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the meta-analysis, suggesting a consistent drug effect. 
Sotagliflozin at 400 mg/day was significantly more 
effective than 200 mg/day at improving time in range, 
average daily glucose, and mean amplitude of glucose 
excursion (supplementary table 4).
Daily total, basal, and bolus insulin dose
Compared with placebo, sotagliflozin reduced daily 
total (weighted mean difference −8.99%, 95% 
confidence interval −10.93% to −7.05%, P<0.001, 
I2=33%, 10 comparisons, 3238 participants), basal 
(−8.03%, −10.14% to −5.93%, P<0.001, I2=0%, 
10 comparisons, 3238 participants), and bolus 
(−9.14%, −12.17% to −6.12%, P<0.001, I2=67%, 
10 comparisons, 3238 participants) insulin dose in 
patients with type 1 diabetes (supplementary figure 
5). Heterogeneity for bolus insulin dose was high, and 
was accounted for by significant subgroup differences 
between high dose (400 mg/day) and low dose (200 
mg/day) sotagliflozin (supplementary table 4).
Urinary glucose excretion
Pooled data came from two randomised controlled 
trials.26 28 They indicated that daily urinary glucose 
excretion progressively increased with increasing 
sotagliflozin dose from 75 mg/day to 200 mg/day, 
but then urinary glucose excretion reached a plateau 
at around 60 g/day with either 200 mg/day and 400 
mg/day of sotagliflozin (supplementary figure 6; 
supplementary table 4)
Non-glycaemic outcomes
Body weight
Compared with controls, sotagliflozin induced a 
significant weight reduction (weighted mean difference 
−3.54%, 95% confidence interval −3.98% to −3.09%, 
P<0.001, I2=18%, 10 comparisons, 3238 participants; 
fig 3). On meta-regression analysis, weight change (%) 
correlated with the magnitude of total insulin dose 
reduction from baseline (β=0.213; P=0.001).
Blood pressure
Compared with placebo, sotagliflozin use was associated 
with a reduction in systolic blood pressure (weighted 
mean difference −3.85 mm Hg, 95% confidence interval 
−4.76 to −2.93, P<0.001, I2=0%) and in diastolic blood 
pressure (−1.43 mm Hg, −1.98 to −0.89, P<0.001, 
I2=0%, 10 comparisons, 3238 participants; fig 3). These 
effects were not associated with an increased incidence 
of ortostatic hypotension (data not shown).
Renal effects: estimated glomerular filtration rate 
and urinary albumin:creatinine ratio 
Compared with placebo, sotagliflozin treatment was 
associated with a slight reduction in eGFR (weighted 
mean difference −0.80 mL/min/1.73 m2, 95% 
confidence interval −1.42 to −0.18, P=0.01, I2=0%, 10 
comparisons, 3238 participants; fig 4). The reduction 
in eGFR occurred only with sotagliflozin at 200 mg/
day (fig 4; supplementary table 4). Subgroup analysis 
showed that the eGFR reduction was observed only in 
randomised controlled trials lasting 12 weeks or less, 
but not in trials of longer duration (supplementary 
table 3). Urinary ACR was evaluated in three phase 
III randomised controlled trials (2977 participants, 
with trial duration ranging 24-52 weeks, and mean 
baseline ACR of participants of 52.6, 31.6, 54.3 mg/g, 
respectively).29-31 Pooled analysis of these trials showed 
that sotagliflozin was associated with a decrease in 
ACR (weighted mean difference −14.57 mg/g, 95% 
confidence interval −2.28 to −26.87, P=0.02, I2=0%, 
five comparisons; fig 4).
To gain further insight into the effect of time on 
renal function, we examined the effect of sotagliflozin 
on eGFR in the two longest trials (duration 52 weeks) 
during the initial 24 weeks and during the following 
28 weeks. While sotagliflozin continued to reduce 
ACR throughout the treatment period, the difference 
in eGFR between sotagliflozin and placebo varied 
during follow-up. During the initial 24 weeks, patients 
receiving sotagliflozin showed a decline in eGFR, both 
in absolute terms and as compared with controls. But 
in the following 28 weeks, the trend was inverted and 
sotagliflozin induced a significant eGFR increase, 
both in absolute terms and as compared with controls 
(supplementary figure 7A-B).
Plasma lipids
No randomised controlled trial reported the effect of 
active treatment or placebo on low density lipoprotein-
cholesterol, high density lipoprotein-cholesterol, or 
triglyceride.
Safety outcomes
Hypoglycaemia and severe hypoglycaemia
The definitions of hypoglycaemia and severe 
hypoglycaemia were consistent across all randomised 
controlled trials and in line with current guideline 
recommendations (supplementary text). Compared 
with placebo, sotagliflozin treatment was associated 
with a lower rate of hypoglycaemia events (weighted 
mean difference −9.09 events per patient year, 95% 
confidence interval −13.82 to −4.36, P<0.001, I2=0%, 
10 comparisons, 3238 participants) and with a 31% 
lower risk of severe hypoglycaemia (relative risk 0.69, 
0.49 to 0.98, P=0.04, 10 comparisons, I2=0%; fig 5).
Diabetic ketoacidosis
Compared with placebo, sotagliflozin was associated 
with an increased risk of diabetic ketoacidosis (relative 
risk 3.93, 95% confidence interval 1.94 to 7.96, 
P<0.001; 10 comparisons, I2=0%, 3238 participants, 
trial duration 4-52 weeks; fig 5). Forty six (69%) of all 
cases of diabetic ketoacidosis occurred at blood glucose 
levels higher than 250 mg/dL, while the remaining 21 
(31%) cases occurred with blood glucose values of 150-
250 mg/dL (supplementary table 5). The risk for diabetic 
ketoacidosis was increased for patients on multiple daily 
injections (3.22, 1.24 to 9.09, P=0.01; 10 comparisons, 
I2=0%, 2072 patients) as well as for patients on 
continuous subcutaneous infusion (6.40, 2.82 to 15.64, 
P<0.001; 10 comparisons, I2=0%, 1166 patients).
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Favours
sotagliflozin
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control
Favours
sotagliflozin
Favours
control
Body weight changes  from baseline (%)
Sotagliflozin 75 mg/day
  Baker 2017 (inTandem4)
Subtotal
Test for heterogeneity: Not applicable
Test for overall effect: Z=0.97, P=0.33
Sotagliflozin 200 mg/day
  Baker 2017 (inTandem4)
  Buse 2018 (inTandem1)
  Danne 2018 (inTandem2)
Subtotal
Test for heterogeneity: τ2=0.00; χ2=1.25, df=2, P=0.53; I2=0%
Test for overall effect: Z=8.43, P<0.001
Sotagliflozin 400 mg/day
  Baker 2017 (inTandem4)
  Bode 2017
  Buse 2018 (inTandem1)
  Danne 2018 (inTandem2)
  Garg 2017 (inTandem3)
  Sands 2015
Subtotal
Test for heterogeneity: τ2=0.06; χ2=5.73, df=5, P=0.33; I2=13%
Test for overall effect: Z=14.65, P<0.001
Total (95% CI)
Test for heterogeneity: τ2=0.09; χ2=10.91, df=9, P=0.28; I2=18%
Test for overall effect: Z=15.52, P<0.001
Test for subgroup differences: χ²=3.81; df=2, P=0.15; I²=47.6%
SysBP changes from baseline (mm Hg)
Sotagliflozin 75 mg/day
  Baker 2017 (inTandem4)
Subtotal
Test for heterogeneity: Not applicable
Test for overall effect: Z=1.66, P=0.10
Sotagliflozin 200 mg/day
  Baker 2017 (inTandem4)
  Buse 2018 (inTandem1)
  Danne 2018 (inTandem2)
Subtotal
Test for heterogeneity: τ2=0.00; χ2=0.59, df=2, P=0.74; I2=0%
Test for overall effect: Z=2.87, P=0.004
Sotagliflozin 400 mg/day
  Baker 2017 (inTandem4)
  Bode 2017
  Buse 2018 (inTandem1)
  Danne 2018 (inTandem2)
  Garg 2017 (inTandem3)
  Sands 2015
Subtotal
Test for heterogeneity: τ2=0.99; χ2=6.58, df=5, P=0.25; I2=24%
Test for overall effect: Z=5.15, P<0.001
Total (95% CI)
Test for heterogeneity: τ2=0.00; χ2=8.71, df=9, P=0.46; I2=0%
Test for overall effect: Z=8.23, P<0.001
Test for subgroup differences: χ²=1.69; df=2, P=0.43; I²=0%
DiaBP changes from baseline (mm Hg)
Sotagliflozin 75 mg/day
  Baker 2017 (inTandem4)
Subtotal
Test for heterogeneity: Not applicable
Test for overall effect: Z=0.09, P=0.93
Sotagliflozin 200 mg/day
  Baker 2017 (inTandem4)
  Buse 2018 (inTandem1)
  Danne 2018 (inTandem2)
Subtotal
Test for heterogeneity: τ2=0.00; χ2=0.05, df=2, P=0.98; I2=0%
Test for overall effect: Z=2.51, P=0.01
Sotagliflozin 400 mg/day
  Baker 2017 (inTandem4)
  Bode 2017
  Buse 2018 (inTandem1)
  Danne 2018 (inTandem2)
  Garg 2017 (inTandem3)
  Sands 2015
Subtotal
Test for heterogeneity: τ2=0.00; χ2=4.34, df=5, P=0.50; I2=0%
Test for overall effect: Z=4.57, P<0.001
Total (95% CI)
Test for heterogeneity: τ2=0.00; χ2=4.68, df=9, P=0.86; I2=0%
Test for overall effect: Z=5.18, P<0.001
Test for subgroup differences: χ²=0.30; df=2, P=0.86; I²=0%
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Fig 3 | Forest plot comparing effect of sotagliflozin versus placebo on body weight, systolic blood pressure (sysBP), 
and diastolic blood pressure (diaBP). IV=inverse invariance
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Subgroup analyses showed that the risk of diabetic 
ketoacidosis varied according to the initial HbA1c 
of included randomised controlled trials. The risk 
increased in trials with a mean initial HbA1c lower 
than 8% (relative risk 6.62, 95% confidence interval 
2.04 to 21.48, I2=0%, P=0.002, n=3 trials, 1608 
participants), but not in trials with a mean HbA1c 
of 8% or more (2.21, 0.43 to 11.42, I2=0%, P=0.34, 
n=3 trials, 1630 participants; supplementary table 
3). In a meta-regression model including sotagliflozin 
dose, trial duration, initial HbA1c, initial fasting 
plasma glucose, changes in HbA1c and fasting 
plasma glucose, total bolus and basal insulin doses 
(baseline, changes, and end-of-treatment doses), 
fasting and postprandial glycaemia, body weight 
changes, and volume depletion events, the risk of 
diabetic ketoacidosis correlated inversely with initial 
HbA1c (β=−0.331; P=0.009) and with the magnitude 
of basal insulin dose reduction (β=−0.218; P=0.012; 
supplementary figure 8).
Urinary tract infections and genital tract infections
Compared with placebo, sotagliflozin did not affect 
the risk of urinary tract infections (relative risk 0.97, 
95% confidence interval 0.71 to 1.33, P=0.84; 10 
comparisons, I2=0%, 3238 participants) but was 
associated with an increased risk of mycotic genital 
tract infections (3.12, 2.14 to 4.54, P<0.001; 10 
comparisons, I2=0%; fig 6). In a meta-regression 
model, the risk of genital tract infection was not related 
to sotagliflozin dose, urinary glucose excretion, initial 
HbA1c, initial fasting plasma glucose, and changes in 
HbA1c and fasting plasma glucose (all P>0.5).
Gastrointestinal events
Compared with controls, sotagliflozin was associated 
with an increased risk of diarrhoea (relative risk 
1.50, 95% confidence interval 1.08 to 2.10, 
P=0.02; 10 comparisons, I2=0%, 3238 participants; 
supplementary figure 9A), but not of other 
gastrointestinal symptoms (supplementary table 5).
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Fig 4 | Forest plot comparing effect of sotagliflozin versus placebo on estimated glomerular filtration rate (eGFR) and 
urinary albumin:creatinine ratio (ACR). IV=inverse invariance
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  Baker 2017 (inTandem4)
  Bode 2017
  Buse 2018 (inTandem1)
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  Garg 2017 (inTandem3)
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Test for heterogeneity: τ2=0.00; χ2=2.53, df=5, P=0.77; I2=0%
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Test for overall effect: Z=1.83, P=0.07
Total (95% CI)
Test for heterogeneity: τ2=0.00; χ2=4.18, df=9, P=0.90; I2=0%
Test for overall effect: Z=2.07, P=0.04
Test for subgroup differences: χ²=1.48; df=2, P=0.48; I²=0%
Incident DKA
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  Buse 2018 (inTandem1)
  Danne 2018 (inTandem2)
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Test for heterogeneity: τ2=0.00; χ2=0.80, df=2, P=0.67; I2=0%
Test for overall effect: Z=1.72, P=0.09
Sotagliflozin 400 mg/day
  Baker 2017 (inTandem4)
  Bode 2017
  Buse 2018 (inTandem1)
  Danne 2018 (inTandem2)
  Garg 2017 (inTandem3)
  Sands 2015
Subtotal
Test for heterogeneity: τ2=0.00; χ2=4.18, df=5, P=0.52; I2=0%
Test for overall effect: Z=3.50, P<0.001
Total (95% CI)
Test for heterogeneity: τ2=0.00; χ2=5.75, df=9, P=0.76; I2=0%
Test for overall effect: Z=3.80, P<0.001
Test for subgroup differences: χ²=0.73; df=2, P=0.69; I²=0%
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Fig 5 | Forest plot comparing effect of sotagliflozin versus placebo on hypoglycaemia, severe hypoglycaemia, and 
diabetic ketoacidosis (DKA). IV=inverse invariance; M-H=Mantel-Haenszel
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Other adverse events
Compared with controls, sotagliflozin treatment was 
associated with an increased risk of acidosis related 
adverse events (relative risk 3.85, 95% confidence 
interval 2.33 to 6.36, P<0.001; 10 comparisons, 
I2=0%) and volume depletion events (2.19, 1.10 
to 4.36, P=0.03; 10 comparisons=10, I2=0%; 
supplementary figure 9B; supplementary figure 
10A; supplementary table 5). Subgroup analysis 
revealed that the risk of volume depletion events 
was increased in the first 12 weeks of treatment, but 
then subsided (supplementary table 3). Sotagliflozin 
did not affect the risk of MACE (1.06, 0.40 to 
2.82, P=0.91; 10 comparisons, I2=6%), cancer 
(0.86, 0.25 to 2.97, P=0.81; nine comparisons, 
I2=0%), or all cause death (0.35, 0.07 to 1.71, 
P=0.19; nine comparisons, I2=0%; supplementary 
table 5; supplementary figure 10B). The effect of 
sotagliflozin on other adverse events is summarised 
in supplementary table 5.
Adverse events leading to treatment discontinuation
We then evaluated the proportion of patients 
experiencing each adverse event who discontinued 
treatment due to the adverse event. The most common 
adverse events leading to treatment discontinuation 
were diabetic ketoacidosis (35.8% of all patients 
with diabetic ketoacidosis discontinued treatment), 
diarrhoea (6.9%), genital tract infections (6.3%), 
severe hypoglycaemia (5.6%), urinary tract 
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Total (95% CI)
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Fig 6 | Forest plot comparing effect of sotagliflozin versus placebo on urinary tract infection (UTI) and genital tract 
infection (GTI). M-H=Mantel-Haenszel
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infections (4.4%), and volume depletion events 
(4.3%).
Dose-response analysis
We analysed dose-response interactions within the three 
randomised controlled trials that evaluated different 
sotagliflozin doses. One trial evaluated sotagliflozin 75, 
200, and 400 mg/day doses,28 while two trials assessed 
the 200 and 400 mg/daydoses30 31 (supplementary table 
1). The 200 mg/day dose had a greater glycosuric effect 
(urinary glucose excretion) than the 75 mg/day dose 
(weighted mean difference 16.00 g/day, 95% confidence 
interval 3.06 to 28.94), but this effect did not increase 
further with the 400 mg/day dose (13.00 g/day, −1.78 to 
27.78; supplementary table 4).
Sotagliflozin 400 mg/day was associated with a 
greater improvement than the 200 mg/day dose in 
HbA1c (weighted mean difference −0.22%, 95% 
confidence interval −0.28% to −0.12%); fasting 
plasma glucose (−9.82 mg/dL, −17.05 to −2.58); 
2h-PPG (−20.51 mg/dL, −33.98 to −7.03); time in 
range (6.48%, 2.97% to 9.99%); average daily glucose 
(−11.02 mg/dL, −17.70 to −4.33); daily total (−5.25%, 
−7.66% to −2.84%), basal (−4.64%, −8.64% to 
−0.64%), and bolus (−7.85%, −11.96% to −3.75%) 
insulin dose; body weight (−0.96%, −1.55 to −0.37); 
systolic blood pressure (−2.51 mm Hg, −3.83 to −1.20); 
eGFR (1.05 mL/min/1.73 m2, 0.11 to 22.12); and ACR 
(−12.29 mg/g, −26.81 to −1.23; supplementary table 
4). We did not find any association between different 
sotagliflozin doses and adverse events. The results of 
the within-trial comparison were all confirmed by the 
across-trial approach.
Sensitivity analyses
Sensitivity analysis conducted by alternative pooling 
methods including Peto’s odds ratio, which has a 
greater power at event rates below 1%,54 confirmed the 
results of the main analysis (supplementary table 3).
Grading of evidence
Quality of evidence was downgraded to moderate for 
effect on time-in-range glucose, because it was unclear 
whether the population undergoing substudies of 
continuous glucose monitoring was representative 
of the whole study population (table 1). Quality of 
evidence was downgraded to low for MACE and all 
cause mortality because of imprecision (table 2).
Discussion
Our analysis had four main findings. Firstly, in patients 
with type 1 diabetes, sotagliflozin as add-on treatment 
to insulin ameliorated glycaemic efficacy outcomes 
and also showed non-glycaemic benefits, including 
body weight, blood pressure, and nephropathy marker 
reduction. Secondly, sotagliflozin treatment was 
Table 1 | Sotagliflozin versus placebo: quality of evidence for clinically relevant glycaemic and non-glycaemic effect outcomes in type 1 diabetes. 
Summary of findings table based on the GRADE approach*
Outcomes and follow-up
Anticipated absolute effects (95% CI)† Relative effect 
(95% CI)
No of participants  
(and RCTs)
Certainty of  
evidence (GRADE) CommentsRisk with placebo Risk with sotagliflozin
Sotagliflozin v placebo for type 1 diabetes: glycaemic effect outcomes
Mean change in HbA1c (%); 
follow-up 4-52 weeks
Mean change: ranged 
from −0.99% to 
0.04%
Mean change in intervention 
group: 0.34% (0.41% to 
0.27%) lower
— 3238 (6) High
Large effect. Dose-response 
gradient across 200-400 
mg/day doses
Mean change in fasting plasma 
glucose (mg/dL); 
follow-up 4-52 weeks
Mean change: ranged 
from −11 to 39 
mg/dL
Mean change in intervention 
group: 16.98 mg/dL (22.09 
to 11.86) lower
— 3238 (6) High
Large effect. Dose-response 
gradient across 200-400 
mg/day doses
Mean change in 2 hour-post-
prandial plasma glucose (mg/
dL); follow-up 4-52 weeks
Mean change: ranged 
from −18.5 to 0 
mg/dL
Mean change in intervention 
group: 39.24 mg/dL (50.42 
to 28.06) lower
— 539 (5) High
Large effect. Dose-response 
gradient across 200-400 
mg/day doses
Mean change of time in range 
(%; 70-180 mg/dL); follow-up 
4-52 weeks
Mean change: ranged 
from −1.83% to 
−0.2%
Mean change in intervention 
group: 9.73% (6.66% to 
12.81%) higher
— 398 (4) Moderate‡
Large effect. Dose-response 
gradient across 200-400 
mg/day doses
Sotagliflozin v placebo for type 1 diabetes: non-glycaemic effect outcomes
Mean change in body weight (%); 
follow-up 4-52 weeks
Mean change: ranged 
from −0.99 to 0.04%
Mean change in intervention 
group: 3.54% (3.98% to 
3.09%) lower
— 3238 (6) High
Dose-response gradient 
across 200-400 mg/day 
doses
Mean change in systolic blood 
pressure (mm Hg); follow-up 
4-52 weeks
Mean change: ranged 
from −3.8 to 1.7 
mm Hg
Mean change in intervention 
group: 3.85 mm Hg (4.76 to 
2.93) lower
— 3238 (6) High
Dose-response gradient 
across 200-400 mg/day 
doses
Mean change in eGFR (mL/
min/1.73 m2); follow-up 4-52 
weeks
Mean change: ranged 
from −1.09 to 0.34 
mL/min/1.73 m2
Mean change in intervention 
group: 0.8 mL/min/1.73 m2 
(1.42 to 0.18) lower
— 3238 (6) High
Dose-response gradient 
across 200-400 mg/day 
doses
Mean change in urinary ACR 
(mg/g); follow-up: range 24 
weeks to 52 weeks
Mean change: ranged 
from 4.1 to 14.9 
mg/g
Mean change in intervention 
group: 14.57 mg/g (26.87 
to 2.28) lower
— 2977 (3) High
Dose-response gradient 
across 200-400 mg/day 
doses
1 mg/dL=0.0555 mmol/L. 
GRADE=grading of recommendations assessment, development, and evaluation; RCT=randomised controlled trial; eGFR=estimated glomerular filtration rate; ACR=albumin:creatinine ratio.
*GRADE working group grades of evidence: high certainty (very confident that the true effect lies close to that of the estimate of the effect); moderate certainty (moderately confident in the effect 
estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different); low certainty (confidence in the effect estimate is limited; the 
true effect could be substantially different from the estimate of the effect); very low certainty (very little confidence in the effect estimate; the true effect is likely to be substantially different from 
the estimate of effect).
†Risk (95% confidence interval) in the intervention group is based on the assumed risk in the comparison group and the relative effect (95% confidence interval) of the intervention. 
‡Unclear whether the population undergoing continuous glucose monitoring substudies was representative of the whole trial population in the inTandem1 and inTandem2 trials. For calculation 
of the optimal information size, α=0.05 and β=0.2 was used.
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associated with a significant reduction in the incidence 
of hypoglycaemia and severe hypoglycaemia. Thirdly, 
diabetic ketoacidosis was the most serious and 
frequent adverse event associated with sotagliflozin 
treatment, which also increased the risk of genital tract 
infections, diarrhoea, and volume depletion events, 
but not of urinary tract infections. Finally, the risk 
of diabetic ketoacidosis varied depending on initial 
HbA1c levels and basal insulin dose reduction. 
Of patients with type 1 diabetes, 30% achieve 
glycaemic goals, up to 20% have severe hypoglycaemia 
every year, and 40% are overweight,3 hence urgently 
needing adjunctive treatment strategies to complement 
the glucose lowering effects of insulin and mitigate its 
unwanted effects. Hypoglycaemia, which results from 
the total dependence of patients with type 1 diabetes 
on injected insulin, is of particular concern and can be 
viewed as the highest unmet need in this population,9 10 
because it is the main factor limiting optimal glucose 
control. Furthermore, severe hypoglycaemia is a strong 
predictor of adverse clinical outcomes and death in 
patients with diabetes.7-18 60
None of the drugs recently approved for type 2 
diabetes and seeking an indication for type 1 diabetes 
(including incretin analogues and SGLT2 inhibitors) 
reduced hypoglycaemic risk, which is either unaffected 
or increased by these treatments.22 61 62 Several 
mechanisms could underlie the hypoglycaemic 
risk reduction observed with sotagliflozin. The dual 
intestinal SGLT1 and renal SGLT2 inhibition blunts acute 
glucose fluctuations and reduces glycaemic variability 
(supplementary figure 4C-D), thereby limiting the need 
for bolus insulin correction doses and the attendant 
hypoglycaemic risk (supplementary figure  5C).15 16 63 
The reduction in the rate of hypoglycaemic events could 
have itself contributed to reduce severe hypoglycaemia. 
The recurrence of hypoglycaemic episodes blunts 
autonomic and hormonal responses to subsequent 
hypoglycaemia, impairs hypoglycaemia awareness and 
glucose counter-regulation, and paves the way to severe 
hypoglycaemia. This functional impairment in counter-
regulatory mechanisms is distinct from autonomic 
neuropathy, occurs in the short term, and can be rapidly 
reversed by reducing hypoglycaemia recurrence.64
The analysis of pooled results from phase III 
randomised controlled trials also showed potential 
renoprotection for sotagliflozin, which reduced 
microalbuminuria, a marker of early diabetic 
nephropathy and an independent cardiovascular risk 
factor (fig 4).19 The transient eGFR decline observed 
in the initial 12 weeks of treatment is similar to 
that observed with other SGLT2 inhibitors65 and 
is consistent with renoprotective mechanisms of 
SGLT2 inhibition, which enhance afferent arteriolar 
tone, reduce intraglomerular pressure, and relieve 
glomerular hyperfiltration and barrier damage.66 
However, in patients receiving sotagliflozin, the 
reduced glomerular perfusion could be aggravated by 
volume depletion favoured by concomitant osmotic 
glycosuria (due to renal SGLT2 inhibition) and 
diarrhoea (induced by intestinal SGLT1 inhibition; 
supplementary figure 9). Hence, volume depletion 
should be avoided in the early months of sotagliflozin 
treatment.
Table 2 | Sotagliflozin versus placebo: quality of evidence for clinically relevant adverse events in type 1 diabetes. Summary of findings table based on 
the GRADE approach*
Outcomes and follow-up
Anticipated absolute effects (95% CI)† Risk ratio 
(95% CI)
No of participants  
(and RCTs)
Certainty of evi-
dence (GRADE) CommentsRisk with placebo Risk with sotagliflozin
Mean change in hypoglycaemia 
events (events per patient year); 
follow-up 4-52 weeks
Mean change: ranged 
from 69 to 179 events 
per patient year
Mean change in intervention 
group: 9.09 events per patient 
year (13.82 to 4.36) lower
— 3238 (6) High —
Incidence of severe hypoglycae-
mia; follow-up 4-52 weeks 43 per 1000 30 per 1000 (21 to 42) 0.69 (0.49 to 0.98) 3238 (6) High —
Incidence of diabetic ketoacido-
sis; follow-up 4-52 weeks 5 per 1000 18 per 1000 (9 to 36) 3.93 (1.94 to 7.96) 3238 (6) High Large effect
Incidence of urinary tract infec-
tions; follow-up 4-52 weeks 48 per 1000 46 per 1000 (34 to 63) 0.97 (0.71 to 1.33) 3238 (6) High — 
Incidence of genital tract infec-
tions; follow-up 4-52 weeks 23 per 1000 73 per 1000 (50 to 106) 3.12 (2.14 to 4.54) 3238 (6) High Large effect
Incidence of diarrhoea; follow-up 
4-52 weeks 35 per 1000 52 per 1000 (37 to 73) 1.50 (1.08 to 2.10) 3238 (6) High —
Incidence of adverse events lead-
ing to treatment discontinuation; 
follow-up 4-52 weeks
23 per 1000 31 per 1000 (18 to 54) 1.34 (0.78 to 2.30) 3238 (6) High —
Incidence of serious adverse 
events; follow-up 4-52 weeks 69 per 1000 76 per 1.000 (58 to 99) 1.11 (0.85 to 1.44) 3238 (6) High —
Incidence of major adverse 
cardiovascular events; follow-up: 
4-52 weeks
5 per 1000 6 per 1000 (2 to 15) 1.06 (0.40 to 2.82) 3238 (6) Low‡ Few events, OIS not reached
All cause mortality; follow-up 
4-52 weeks 2 per 1000 1 per 1000 (0 to 4) 0.34 (0.07 to 1.70) 3238 (6) Low‡
Few events, OIS 
not reached
GRADE=grading of recommendations assessment, development, and evaluation; RCT=randomised controlled trial; OIS=optimal information size.
*GRADE working group grades of evidence: high certainty (very confident that the true effect lies close to that of the estimate of the effect); moderate certainty (moderately confident in the effect 
estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different); low certainty (confidence in the effect estimate is limited; the 
true effect could be substantially different from the estimate of the effect); very low certainty (very little confidence in the effect estimate; the true effect is likely to be substantially different from 
the estimate of effect).
†Risk (95% confidence interval) in the intervention group is based on the assumed risk in the comparison group and the relative effect (95% confidence interval) of the intervention. 
‡Downgraded for imprecision. For calculation of the OIS, α=0.05 and β=0.2 was used.
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By contrast with SGLT2 inhibitors, sotagliflozin did 
not increase the risk of urinary tract infections (fig 
6). The reduced glycosuric effects of sotagliflozin as 
compared with SGLT2 inhibitors62 could have limited 
the incidence of urinary tract infections, while SGLT1 
mediated intestinal glucose malabsorption could have 
increased diarrhoea, usually mild, thereby self limiting 
and not inducing treatment discontinuation.
Further supporting the relevance of intestinal 
SGLT1 inhibition, a dose-response gradient for most 
glycaemic outcomes was observed with increasing 
sotagliflozin dose, not paralleled by an increase in 
glycosuria, which reached a plateau at 60 g/day, 40-
50% lower than that reported with full dose SGLT2 
inhibitors67 68 (supplementary figure 6). Whether 
sotagliflozin maintains unaltered glucose lowering 
efficacy in the presence of moderate-to-severe renal 
failure will be assessed by ongoing trials in type 2 
diabetes (supplementary table 2).
Diabetic ketoacidosis was the most common 
relevant adverse event, observed in 61 (3.1%) of 1912 
sotagliflozin treated patients and inducing treatment 
discontinuation in 38% (supplementary table 5). 
While SGLT2 inhibitor associated diabetic ketoacidosis 
has been reported to occur often at uncharacteristically 
normal or mildly elevated levels (<250 mg/dL) of blood 
glucose (euglycaemic diabetic ketoacidosis),69 over two 
thirds of occurrences of sotagliflozin related diabetic 
ketoacidosis happened at high blood glucose levels 
(supplementary table 5). Notably, our data indicate 
that a lower initial HbA1c and a greater reduction 
in basal insulin dose during sotagliflozin treatment 
could increase the risk for diabetic ketoacidosis 
(supplementary figure 8; supplementary table 3), 
possibly because patients with less deteriorated 
baseline glycaemic control experienced a more rapid 
down-titration of insulin dose with sotagliflozin. The 
extent of basal insulin down-titration seems central 
for diabetic ketoacidosis development by allowing 
unrestricted fasting induced lipolysis and ketogenesis 
on a background of negative glucose balance.69 
Consistently, insulin dose reduction of more than 20% 
has been found to increase ketone levels and diminish 
the glucose lowering effect of SGLT2 inhibitors.70
Clinical and policy implications
Sotagliflozin treatment for up to 52 weeks provides 
consistent glycaemic and non-glycaemic benefits 
in patients with type 1 diabetes, including the 
reduction of unwanted effects of insulin treatment 
(that is, weight gain and hypoglycaemia). These 
effects make sotagliflozin an attractive adjunctive 
treatment to insulin in patients with type 1 diabetes, 
of whom 30% achieve target glycaemic goals, 40% are 
overweight, and up to 20% per year experience severe 
hypoglycaemia.3 The clinical impact of these benefits 
might be more appreciable in patients at higher risk 
of severe hypoglycaemia, such as those with recurrent 
hypoglycaemia and hypoglycaemia unawareness, who 
represent 17-36% of the general population with type 
1 diabetes.71
Our analysis could also help minimise the risk of 
diabetic ketoacidosis in type 1 diabetes treated with 
sotagliflozin by appropriate patient selection and by 
defining appropriate protocols for basal insulin dose 
adjustment. Ketone testing should be performed 
after each basal insulin dose reduction, rather 
than relying solely on overt triggering conditions or 
symptoms of diabetic ketoacidosis,28-31 which often 
fail to recognise early diabetic ketoacidosis.72 Future 
research should define safer protocols for basal insulin 
dose adjustment. For example, in a recent phase III 
randomised controlled trial with dapagliflozin that 
reported no increased risk of diabetic ketoacidosis, 
participants were instructed to reduce insulin doses 
by no more than 20% on treatment initiation, to 
measure ketonaemia whenever glucose readings were 
consistently elevated, and then subsequently to up-
titrate insulin doses back to baseline after positive 
ketone testing.73
Strengths and limitations
Strengths and limitations of our analysis come from 
the characteristics of included evidence. Strengths 
include the thorough assessment of efficacy and 
safety outcomes, and the direct impact of extracted 
evidence regarding relevant clinical outcomes (such 
as hypoglycaemia and diabetic ketoacidosis) on 
decision making in the management of type 1 diabetes. 
Limitations include the relatively small number and 
short duration of included trials (not exceeding 52 
weeks), which prevented robust assessment of long 
term hard outcomes such as MACE and overall mortality. 
Furthermore, although all included randomised 
controlled trials had good methodological quality, 66% 
were industry funded, which could make them liable 
to sponsorship bias.45 Recent guidelines recommend 
against automatically downgrading industry funded 
trials and we therefore address this issue by verifying 
a list of items empirically linked by recent literature to 
biased outcomes in industry funded trials.43
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